Literature DB >> 15187198

The effect of proteinase inhibitors on glomerular albumin permeability induced in vitro by serum from patients with idiopathic focal segmental glomerulosclerosis.

Michele Carraro1, Cristina Zennaro, Mary Artero, Giovanni Candiano, Gian Marco Ghiggeri, Luca Musante, Cristina Sirch, Maurizio Bruschi, Luigi Faccini.   

Abstract

BACKGROUND: The putative circulating factor responsible for the glomerular permeability alterations induced in vitro by serum from patients affected by focal segmental glomerulosclerosis (FSGS) remains unidentified. We have observed that a serine proteinase isolated from patient serum increases albumin permeability in isolated glomeruli. The objective of the present study was to determine the effect of various proteinase inhibitors on glomerular albumin permeability (P(alb)) in isolated glomeruli incubated with FSGS serum.
METHODS: The study population consisted of 12 FSGS patients (eight males; mean age: 21+/-10 years) previously shown to have elevated serum albumin permeability activity. P(alb) was determined by measuring the change in glomerular volume induced by applying oncotic gradients to isolated healthy rat glomeruli treated with patient serum in comparison to control serum. Solutions of seven different proteinase inhibitors (0.5 mg/ml) were added to the incubation media with the sera (1:1 vol/vol): serine proteinase inhibitors (PMSF, leupeptin, aprotinin, gabexate mesylate), the cysteine proteinase inhibitor E-64, the metalloproteinase inhibitor EDTA and the aspartate proteinase inhibitor pepstatin. Sera from the same patients were also tested with the addition to the incubation media of quinaprilat, an inhibitor of the metalloproteinase angiotensin-converting enzyme.
RESULTS: Mean P(alb) of the sera was 0.86+/-0.11, with the addition of PMSF 0.41+/-0.09, leupeptin 0.30+/-0.17, aprotinin 0.09+/-0.14, gabexate mesylate 0.27+/-0.25, E-64 0.81+/-0.09, EDTA 0.68+/-0.10 or pepstatin 0.76+/-0.11. The mean P(alb) of the sera combined with quinaprilat was reduced to 0.34+/-0.35. Thus, only the serine proteinase inhibitors consistently blocked the increased P(alb) induced by the FSGS sera.
CONCLUSIONS: In the cascade of events that lead to the initiation of glomerular fibrosis in FSGS, the putative glomerular permeability factor associated with FSGS may require a serine proteinase to effect its activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187198     DOI: 10.1093/ndt/gfh343

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Recurrent focal segmental glomerulosclerosis after kidney transplantation.

Authors:  Rebecca Trachtman; Simranjeet S Sran; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2015-02-19       Impact factor: 3.714

2.  Altered activity of plasma hemopexin in patients with minimal change disease in relapse.

Authors:  Winston W Bakker; Catharina M L van Dael; Leonie J W M Pierik; Joanna A E van Wijk; Jeroen Nauta; Theo Borghuis; Jola J Kapojos
Journal:  Pediatr Nephrol       Date:  2005-08-04       Impact factor: 3.714

Review 3.  Minimal change nephropathy and focal segmental glomerulosclerosis.

Authors:  Peter W Mathieson
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

4.  Pathogenic pathways are activated in each major cell type of the glomerulus in the Cd2ap mutant mouse model of focal segmental glomerulosclerosis.

Authors:  Eric W Brunskill; S Steven Potter
Journal:  BMC Nephrol       Date:  2015-05-13       Impact factor: 2.388

5.  A misprocessed form of Apolipoprotein A-I is specifically associated with recurrent Focal Segmental Glomerulosclerosis.

Authors:  Conxita Jacobs-Cachá; Natàlia Puig-Gay; Dominic Helm; Mandy Rettel; Joana Sellarès; Anna Meseguer; Mikhail M Savitski; Francesc J Moreso; Maria José Soler; Daniel Seron; Joan Lopez-Hellin
Journal:  Sci Rep       Date:  2020-01-24       Impact factor: 4.379

6.  Podocyte expression of membrane transporters involved in puromycin aminonucleoside-mediated injury.

Authors:  Cristina Zennaro; Maria Pia Rastaldi; Lorella Pascolo; Marco Stebel; Elisa Trevisan; Mary Artero; Claudio Tiribelli; Vittorio Di Maso; Michele Carraro
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.